All posts related to "biosimilars"

EULAR News – June 15, 2018

newspaper in mail slot

“New drugs – new perspectives: clinical and regulatory issues concerning biosimilars” – Professor Tore Kvien

During the session, “New drugs – new perspectives: clinical and regulatory issues concerning biosimilars,” Professor Tore Kvien, head of the department of rheumatology at the Diakonhjemmet Hospital in Oslo, updated EULAR delegates on the latest issues and evidence on the use of biosimilars.

ACE is the leader in Canada providing patient information and education on biosimilars. If this therapy is new to you, please visit the Biosim•Exchange area of our website.
Continue reading

JointHealth™ insight – June 2018

JointHealth™ Education Advanced Therapies for Inflammatory Arthritis – “Knowledge is power!”

JointHealth insight title page
In Arthritis Consumer Experts’ (ACE) June JointHealth™ insight, they introduce their newest JointHealth™ education course, Advanced Therapies for Inflammatory Arthritis.

This edition of JointHealth™ insight covers the following topics:

  • The inspiration behind JointHealth™ education, and other courses offered through the program
  • Conventional and advanced therapies for inflammatory arthritis
  • The importance of understanding therapy choices
  • A lesson plan for JointHealth™ Education Advanced Therapies for Inflammatory Arthritis
  • A rheumatologist’s perspective on the new course
  • A patient “graduate’s” perspective on the new course
  • Other resources related to advanced medications and therapy changes in Canada

To sign up for the JointHealth™ Education Advanced Therapies for Inflammatory Arthritis course, please click here.

EULAR News – ACE is at EULAR 2018!

ACE is sharing the latest research news from this year’s European League Against Arthritis’ (EULAR) Annual European Congress of Rheumatology in Amsterdam, Netherlands.

Banner for EULAR 2018ACE is attending this year’s annual meeting of the European League Against Arthritis (EULAR) in Amsterdam, which will be host to 14,000 participants from more than 120 countries in Europe and around the world. This year, EULAR received more than 5,050 research abstracts – the most ever. The meeting will feature over 175 sessions and 45 themed poster tours with more than 560 speakers showcasing work from 2,256 poster displays. ACE is here to learn the most current information on the impact, burden and cost of arthritis for patients and society, and the improved ability to diagnose and treat different types of arthritis early.

Many of these advances are the product of collaboration between healthcare providers and patients and patient organizations like ACE. We will be reporting over the next few days on how this collaboration is advancing models of care and development of advanced therapies.

ACE is also leading a meeting with members of the Global RA Network who are attending EULAR. At the meeting, ACE will facilitate discussion on the development of tools for Global RA Network members to use in their countries to raise awareness and advocate for improved models of care. Based on the 2017 Global RA survey findings, ACE is proposing to develop tools that will improve RA patients’ understanding about the kind and quality of care they should be receiving in their country to improve their disease and overall health.

JointHealth™ insight – Summer 2017 – It’s summertime: What’s hot in arthritis research?

JointHealth™ insight – Summer 2017

It’s summertime: What’s hot in arthritis research?

Jointhealth™ insight screen captureIn this summer issue of JointHealth™ insight, we report on new information presented at the European League Against Rheumatism (EULAR) Annual Congress, which took place in Madrid, Spain, in June 2017. EULAR updates covered include:

  • EULAR’s “Don’t Delay, Connect Today” campaign to improve models of care for inflammatory arthritis
  • Immunogenicity studies that show comparable results between biosimilars and originator biologics
  • Research from Denmark finds no higher patient use of health services after policy transition to biosimilars
  • A best practice spotlight on helping patients understand biosimilars

In this issue, you will also find:

  • Information about a new Osteoarthritis (OA) Tool for family physicians
  • A profile of a young scientist’s research journey looking at osteoarthritis and biomarkers

What’s hot in arthritis research?

Continue reading

New online forum to improve biosimilars education

Arthritis Consumer Experts today announced the launch of the Biosim•Exchange

Arthritis Consumer Experts today announced the launch of the Biosim•Exchange – the first central resource in Canada for consumers to find timely, fact-based information on biosimilars safety and effectiveness and report on public and private health insurance formulary policy or listing decisions on biosimilars.

Biosim Exchange Banner“There is a real need for balanced, evidence-based information on biosimilars. Our aim with the Biosim•Exchange is to help patients better understand biosimilars and their place among other inflammatory arthritis treatments. With this knowledge, patients can have a full therapy conversation with their rheumatologist (or other specialist) in order to best decide on their choice of medications, including originator biologics or biosimilars,” said Cheryl Koehn, Founder & President, Arthritis Consumer Experts.

To view the Biosim•Exchange, please click here: http://bit.ly/JHBiosimExch.

ACE encourages you to share the Biosim•Exchange with other patients, your friends and family.

We look forward to your questions and comments and hearing about your experience with biosimilars.